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Abstract
Purpose: Sorafenib is a multi-targeted tyrosine kinase inhibitor with therapeutic efficacy in several malignancies. Sorafenib
may exert its anti-neoplastic effect in part by altering vascular permeability and reducing intra-tumoral interstitial
hypertension. As correlative science with a phase II study in patients with advanced soft-tissue sarcomas (STS), we evaluated
the impact of this agent on intra-tumor interstitial fluid pressure (IFP), serum circulating biomarkers, and vascular density.
Patients and Methods: Patients with advanced STS with measurable disease and at least one superficial lesion amenable to
biopsy received sorafenib 400 mg twice daily. Intratumoral IFP and plasma and circulating cell biomarkers were measured
before and after 1–2 months of sorafenib administration. Results were analyzed in the context of the primary clinical
endpoint of time-to-progression (TTP).
Results: In 15 patients accrued, the median TTP was 45 days (range 14–228). Intra-tumoral IFP measurements obtained in 6
patients at baseline showed a direct correlation with tumor size. Two patients with stable disease at two months had post-
sorafenib IFP evaluations and demonstrated a decline in IFP and vascular density. Sorafenib significantly increased plasma
VEGF, PlGF, and SDF1a and decreased sVEGFR-2 levels. Increased plasma SDF1a and decreased sVEGFR-2 levels on day 28
correlated with disease progression.
Conclusions: Pretreatment intra-tumoral IFP correlated with tumor size and decreased in two evaluable patients with SD on
sorafenib. Sorafenib also induced changes in circulating biomarkers consistent with expected VEGF pathway blockade,
despite the lack of more striking clinical activity in this small series.
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The bi-aryl urea sorafenib was initially developed as an
inhibitor of c-raf and mutant (V599E) b-raf in vitro [1]. The ras/
raf signaling pathway is an important mediator of responses to
growth signals and angiogenic factors. However, sorafenib also
inhibits several receptor tyrosine kinases that may be involved in
tumor angiogenesis and progression, e.g., human and murine
vascular endothelial growth factor receptor-2 (VEGFR-2),
VEGFR-3, platelet-derived growth factor receptor-beta
(PDGFR-b), Flt3, and c-KIT [2,3,4]. Indeed, in human tumor
xenografts, sorafenib induced a dramatic reduction in tumor neo-
vascularization. These data suggest that sorafenib may have
antineoplastic activity through multiple mechanisms, directly by
targeting cell proliferation/survival dependent on activation of the
MAPK pathway and by inhibiting tumor angiogenesis through
inhibition of VEGFR-2, VEGFR-3, and/or PDGFR-b. Sorafenib
has been approved by the United States Food and Drug
Administration for the treatment of patients with renal cell
carcinoma and hepatocellular carcinoma, and it remains under
investigation in several other solid tumors and hematologic
malignancies.
Studies from our group and others have shown that the intra-
tumoral interstitial fluid pressure (IFP) in human sarcomas,
melanomas, and carcinomas (including colon, breast, lung, head
and neck, cervix) is significantly higher than in normal tissues
[5,6,7,8,9,10,11,12,13,14,15,16,17]. Increased permeability of
blood vessels, impaired interstitial and lymphatic drainage, and
compression of blood vessels by tumor cells growing in a confined
space are major causes of intra-tumoral interstitial hypertension
[18]. VEGF and PDGF signaling pathways have previously been
etiologically related to tumor interstitial hypertension. Antibody
blockade of VEGFR-2 reduces both tumor vascular permeability
and IFP and increases both the transvascular pressure gradient
and penetration of small tracers into solid tumors [19,20].
Similarly, the inhibition of PDGF signaling (by DNA aptamers,
imatinib, etc.) may reduce tumor IFP, increase tumor uptake of
chemotherapy agents, and enhance their therapeutic effects
[21,22,23]. However, responses to antiangiogenic agents are
invariably transient, and the escape mechanisms remain elusive
[24].
Using study drug supplied by the NCI Cancer Therapy
Evaluation Program (CTEP), we conducted a phase II trial of
sorafenib in patients with advanced soft tissue sarcomas (STS),
with the aim of exploring whether sorafenib administration is
associated with mechanistically-related changes in intra-tumoral
IFP and vascular density as well as circulating biomarkers of
angiogenesis.
Methods
Trial Design
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. This phase II study (Figure 1) was approved by the
Institutional Review Board of the Dana-Farber/Harvard Cancer
Center for patients with metastatic or inoperable soft tissue
sarcomas with no available curative or definitive survival-
prolonging palliative therapy. Additional eligibility criteria includ-
ed: at least one site of measurable disease by radiologic imaging, at
least one superficial palpable tumor (.1 cm) with no overlying
viscera amenable to biopsy, age$18 years, Eastern Cooperative
Oncology Group (ECOG) performance status #2, and no prior
sorafenib therapy. Written informed consent was obtained from all
study participants. Sorafenib was administered at 400 mg twice
daily continuously in cycles arbitrarily denoted as 28 days in
length.
Data Acquisition
Evaluations included physical examination, laboratory data,
documentation of ECOG performance status, CT or MRI
imaging (at the discretion of the treating physicians), and
electrocardiogram. Each of these evaluations was performed prior
to initial sorafenib administration, every one to four weeks
(depending on cycle) while on study, and one month after the
last dose of sorafenib was administered. Imaging was performed
every other month while on study. Adverse events and toxicities
were assessed on schedule every one to four weeks (depending on
cycle) and one month after the last dose of sorafenib was
administered. Pharmacokinetic data were measured on days 28
and 56.
Evaluation of Biomarkers
Histology. Biopsies were available from 3 patients at baseline
and after 28 or 56 days of sorafenib therapy. Five mm-thick
sections were cut from the formalin-fixed, paraffin embedded
blocks and a double immunostaining procedure was performed
with CD31 (Dako N1596, Carpentria, CA) and a-smooth muscle
actin (a-SMA; Dako M0850) antibodies. In brief, the CD31
antibody was incubated at room temperature for 1 hour. Slides
were then washed and incubated in secondary antibody (DAKO
EnVision anti-mouse, K4007) for 30 min and developed with
DAB. Slides were then blocked with EnVision doublestain block
for 5 min and incubated overnight with the a-SMA antibody.
After washes, slides were incubated in secondary antibody (DAKO
Doublestain AP Polymer) for 30 min, washed, and developed with
Fast Red. Slides were counterstained with hematoxylin and
coverslipped with Faramount. To determine the percentage of
Figure 1. Flow Diagram.
doi:10.1371/journal.pone.0026331.g001
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with a Ki67 antibody (Dako N1633).
Circulating Biomarkers. Peripheral blood was collected in
EDTA-containing vacutainers from patients enrolled in this study
at baseline (prior to sorafenib administration) and 28 days
following the first dose of sorafenib. Blood was available from 14
patients at baseline and 10 patients at 28 days. Plasma analysis was
carried out for circulating VEGF, placental growth factor (PlGF),
soluble VEGFR-1 (sVEGFR-1), basic fibroblast growth factor
(bFGF), interleukin-1b (IL-1b), IL-6, IL-8, and tumor necrosis
factor-alpha (TNF-a) using multiplex ELISA plates from Meso-
Scale Discovery, as well as for sVEGFR-2 and stromal cell-derived
factor-1-alpha (SDF1a) using kits from R&D Systems [25]. Every
sample was run in duplicate. Blood-circulating CD34
+CD45
dim
progenitor cells (CPCs) and VEGFR-2
+CD45
+ monocytes were
enumerated in fresh samples using a standard flow cytometry
protocol [26]. The quantitative analysis endpoint was the change
in the fraction of CPCs or VEGFR-2
+ monocytes within the
mononuclear blood cell population after sorafenib treatment.
Percent values were obtained pre-treatment and at day 28 after the
first dose of sorafenib.
Intra-Tumoral IFP. Intra-tumoral IFP was measured intra-
operatively as previously described [9] prior to administration of
the first dose of sorafenib and, in the absence of progression or
drug intolerance, repeated on study day 28 or 56. In brief, to
measure IFP, a 23-gauge needle with a 2 mm side hole at 5 mm
from the tip was used. Nylon filaments (6-0 Ethilon) were placed in
the needle. To take the pressure measurements, the needle and
tubing filled with sterile heparinized saline were connected to a
disposable pressure transducer and an electronic data acquisition
and recording system (AdInstruments Inc, Colorado Springs, CO).
The needle and tubing were gas sterilized before use. The
calibration of the pressure transducer was verified by applying
pressures of 10, 20, and 40 mm Hg before each IFP measurement.
With the patient in supine position, the needle was inserted into
the tumor center and the IFP was recorded. Stable pressure
measurements with a good fluid communication between the
tumor interstitial space and needle were considered valid. The IFP
was measured in 2 to 3 different locations within the tumor. All
IFP measurements were performed in superficial tumors under
local anesthetic.
Data and Statistical Analyses
The correlative scientific endpoints of this trial included
measurements of changes in circulating biomarkers and IFP,
radiographic responses, toxicity, and pharmacokinetics. The
primary clinical endpoint was time-to-progression (TTP), mea-
sured from date of registration to date of radiographic progression.
Response and progression were evaluated using the Response
Evaluation Criteria in Solid Tumors (RECIST) [27]. Radiograph-
ic response was defined as percentage change in tumor size.
Biomarker changes from baseline were tested using the exact
paired Wilcoxon test [28]. Missing measurements were excluded
from analysis. In exploratory studies, we tested the correlation of
baseline biomarker or biomarker changes at day 28 with pre-
treatment tumor size, best tumor response (SD), or radiographic
tumor response (as ordinal variables) using Kendall’s tb
coefficients [29].
Results
Demographic Data and Clinical Effects of Sorafenib
Patient and tumor characteristics are listed in Table 1.
Fourteen of 15 patients (93.3%) had received prior chemotherapy
and/or radiation therapy. No patients experienced a complete or
partial radiographic response by RECIST. Stable disease (SD) was
observed in 8 patients (53%) for a median 72 days (range 45–228
days). Progressive disease was observed as the ‘‘best response’’ in
the remaining 7 patients (47%). Median TTP for the entire cohort
was 45 days (range 14 to 228 days). Clinical outcomes did not
appear to correlate with any specific histology; the 4 patients with
TTP.80 days had 4 different sarcoma histologies (desmoplastic
small round cell tumor, leiomyosarcoma, myxofibrosarcoma, and
synovial sarcoma).
Safety
Adverse events probably or definitely related to treatment are
listed in Table 2. No Grade 4 toxicities were noted. The most
commonly observed adverse events were hand-foot syndrome (7
patients), fatigue (3), mucositis/stomatitis (4), and hypertension (3)
(Table 2). Of note, sorafenib administration transiently increased
the number of red blood cells and blood hemoglobin at day 14
(Table S1).
Analyses of Circulating Biomarkers
As a mechanistic pharmacodynamic assessment of sorafenib
administration, we measured circulating levels of angiogenic
biomarkers before and after sorafenib dosing, compared baseline
biomarker levels with baseline tumors characteristics, and
correlated baseline biomarker levels or changes in biomarker
levels with radiographic responses. Sorafenib treatment induced
significant increases in plasma circulating VEGF, PlGF, IL-8, and
Table 1. Clinical characteristics.
Patient characteristics Number (%)
Median age 59 years (range, 30–84 years)
Sex
Male 9 (60)
Female 6 (40)
ECOG* Performance Status
0 8 (53.3)
1 7 (46.7)
Histology
Angiosarcoma 1 (6.7)
Desmoplastic small round cell tumor 1 (6.7)
Gastrointestinal stromal tumor 1 (6.7)
Leiomyosarcoma 4 (26.7)
Liposarcoma 1 (6.7)
Malignant diffuse-type giant cell tumor 1 (6.7)
Malignant peripheral nerve sheath tumor 1 (6.7)
Malignant phyllodes tumor 1 (6.7)
Myxofibrosarcoma 2 (13.3)
Synovial sarcoma 2 (13.3)
Primary site
Upper extremity 1 (6.7)
Lower extremity 1 (6.7)
Trunk 12 (80.0)
Pelvis 1 (6.7)
*ECOG, Eastern Cooperative Oncology Group.
doi:10.1371/journal.pone.0026331.t001
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inflammatory biomarkers (bFGF, sVEGFR-1, TNF-a, IL-6, CPCs
or VEGFR-2
+ monocytes) (Table 3 and not shown). IL-1b
concentration was undetectable in the majority of plasma samples.
Higher baseline plasma concentration of IL-6 correlated with
larger baseline tumor size (p,0.05, Table 4). Lower baseline
plasma PlGF levels correlated with improved radiographic
response after sorafenib dosing (p,0.05, Table 4). With respect
to biomarkers that changed after one cycle of sorafenib (day 28),
the decrease in plasma sVEGFR-2 correlated with both SD and
trend toward improved radiographic response, and the increase in
plasma SDF1a correlated with worse radiographic tumor response
(p,0.05; Table 4). In the samples from patients with SD who
were on-study and evaluable at 56 days, there were no statistically
significant differences in the measured biomarkers, likely due to
the small sample size (n=4; data not shown).
Vascular Density and Maturation and Cancer Cell
Proliferation
To identify blood vessels and perivascular cells in tumor
sections, we performed a double immunostaining procedure with
antibodies against CD31 and a-SMA, respectively. In the biopsies
of 2 patients, the decrease in vessel density was 59% and 83%,
respectively, after sorafenib treatment (Figure 2 and Table 5).
The fraction of a-SMA-positive vessels in these 2 patients was 48%
and 64%, respectively, before sorafenib treatment, and sorafenib
generally reduced the fraction of both a-SMA-negative and -
positive vessels (Table 5). With sorafenib treatment, there was a
trend towards greater reduction in a-SMA-negative than a-SMA-
positive vessels (Table 5). In a third patient the vessel density was
relatively low in the pretreatment biopsies, and increased by
approximately 50% after sorafenib (Table 5). In 2 patients with
sufficient tissue available in both pre- and post-sorafenib biopsies,
we also quantified the number of proliferating cancer cells.
Sorafenib decreased the percentage of proliferating cancer cells
(Ki67-positive) by 27% and 36%, respectively.
Table 2. Adverse events after sorafenib treatment in advanced soft tissue sarcoma patients: number of episodes/number of
affected patients (percentage).
Toxicity Grade 1 (%) Grade 2 (%) Grade 3 (%) Grade 4 (%) Any Grade (%)
Hand-foot syndrome 13/6 (40.0) 5/2 (13.3) 3/3 (20.0) 0 21/7 (46.7)
Rash/desquamation 4/1 (6.7) 2/1 (6.7) 3/1 (6.7) 0 8/1 (6.7)
Fatigue 5/3 (20.0) 0005 / 3 ( 2 0 . 0 )
Mucositis/stomatitis 5/4 (26.7) 0005 / 4 ( 2 6 . 7 )
Hypertension 2/2 (13.3) 0 2/1 (6.7) 0 4/3 (20.0)
Extremity pain 4/1 (6.7) 0004 / 1 (6.7)
Erythema multiforme 2//1 (6.7) 1/1 (6.7) 0 0 3/2 (13.3)
Skin – other 2/2 (13.3) 0 1/1 (6.7) 0 3/2 (13.3)
Hemoglobin 0 2/1 (6.7) 0 0 2/1 (6.7)
Anorexia 2/1 (6.7) 0002 / 1 (6.7)
Bilirubin 2/1 (6.7) 0002 / 1 (6.7)
Oral cavity – pain 2/1 (6.7) 0002 / 1 (6.7)
Platelets 1/1 (6.7) 0001 / 1 (6.7)
Fever without neutropenia 1/1 (6.7) 0001 / 1 (6.7)
Alopecia 1/1 (6.7) 0001 / 1 (6.7)
Pruritis 0 1/1 (6.7) 0 0 1/1 (6.7)
Dehydration 0 0 1/1 (6.7) 0 1/1 (6.7)
Diarrhea 0 1/1 (6.7) 0 0 1/1 (6.7)
Alkaline phosphatase 1/1 (6.7) 0001 / 1 (6.7)
Muscle - pain 1/1 (6.7) 0001 / 1 (6.7)
doi:10.1371/journal.pone.0026331.t002
Table 3. Plasma biomarker concentration (pg/ml) before
(pre-treament) and after 28 days after sorafenib treatment.
Pre-Treatment Day 28
Plasma Biomarker (N=14) (N=10) P-value
VEGF 140 [87,161] 214 [154,311] 0.002
bFGF (pg/ml) 36 [19,68] 29 [15,86] 0.19
PlGF 22 [17,34] 52 [40,62] 0.002
sVEGFR-1 (pg/ml) 112 [99,142] 83 [66,93] 0.38
sVEGFR-2 6212 [5826–7207] 4781 [3942–5484] 0.002
SDF1a 2306 [2218,2582] 2705 [2531,3472] 0.0039
IL-6 (pg/ml) 5.8 [3.9,17.2] 12 [5,33] 0.13
IL-8 5.7 [4.3,14.5] 7.1 [5.6,22.2] 0.0059
TNF-a (pg/ml) 9.2 [7.4,11.8] 9.2 [7.4,14.8] 0.11
CPCs (% of PBMCs) 0.050 [0.030,0.074] 0.057 [0.029,0.075] 0.20
Data are shown as medians and interquartile ranges (in square brackets)
compared to baseline levels. P-values are from Wilcoxon test.
VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor;
PlGF, placental growth factor; sVEGFR-1, soluble VEGF receptor-1; sVEGFR-2,
soluble VEGF receptor-2; SDF1a, stromal cell-derived factor-1-alpha; IL-6,
interleukin-6; IL-8, interleukin-8; TNF-a, tumor necrosis factor-alpha, CPCs,
circulating progenitor cells; PBMC, peripheral blood mononuclear cells.
doi:10.1371/journal.pone.0026331.t003
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IFP measurements were obtained in 6 patients at baseline. The
IFP in the 6 lesions varied between 2.5 and 21.0 mm Hg and
showed a direct correlation with tumor size (Kendall’s tau=0.87,
p=0.017, Table 4). Only 2 of these 6 patients had SD at 28 and
56 days. Thus, corresponding post-sorafenib IFP evaluation was
only performed in these 2 patients. In both, a decline in IFP was
observed. Tumor IFP decreased from 17.0 to 11.5 mm Hg in one
patient and from 3.0 to 0.0 mm Hg in the other. The decrease in
tumor IFP in these 2 patients was associated with a reduction in
vascular density.
Discussion
Studying the physiologic and pharmacodynamic impact of
mechanistically-targeted drugs is a key aspect of rational
therapeutic development and optimization. This study was
designed to assess several mechanism-based correlative studies
along with standard clinical outcomes. In this cohort of patients
with multi-drug refractory STS of varied histologies, sorafenib
administration was associated with modest radiographic effects,
with a median TTP of 45 days. In a recent study of 145 patients
with recurrent or metastatic sarcoma of various histologies treated
with sorafenib, RECIST complete or partial responses were
observed in five patients with angiosarcoma and one with
leiomyosarcoma [30].
While radiographic response criteria have been recently refined
[31], they still do not have the sensitivity to detect accurately the
more subtle responses which reflect the anti-neoplastic and anti-
angiogenic effects of targeted therapies. A set of blood circulating
pro-angiogenic and pro-inflammatory molecules are often elevated
in patients with tumors and are currently being evaluated as
potential biomarkers of response or resistance to treatments such
as anti-VEGF therapy [24]. Consistent with the anti-VEGF
activity of sorafenib––and in agreement with data from trials in
hepatocellular carcinoma patients of another anti-VEGFR TKI
sunitinib––treatment increased the plasma concentration of VEGF
and PlGF, decreased sVEGFR-2, and increased erythropoiesis
[24,32] [33]. More recently, corroborative data from over 700
patients with renal cell carcinoma in a phase III placebo-
controlled randomized trial of sorafenib confirmed that sorafenib
therapy increased VEGF and decreased sVEGRF-2 levels [34].
Table 4. Analysis of correlation between baseline biomarker and biomarker change at day 28 with (i) pre-treatment tumor size, (ii)
best tumor response, and (iii) radiographic tumor response after sorafenib treatment in advanced STS patients (Kendall’s tb with
95% CI).
Kendall’s tb Pre-Treatment Size Response (SD) Radiographic Response
Baseline IFP (N=6)
1 0.87 [0.56,1.17] 20.43 [20.91,0.05] 20.20 [20.63,0.23]
P-value 0.017 0.40 0.82
Baseline IL-6 (N=14)
1 0.42 [0.10,0.74] 0.11 [20.23,0.45] 0.09 [20.36,0.54]
P-value 0.037 0.70 0.74
Baseline PlGF (N=14)
1 0.31 [20.03,0.65] 20.39 [20.64,20.14] 20.61 [20.94,20.27]
P-value 0.12 0.11 0.0054
Change in sVEGFR-2 (N=10)
2 N/A 0.62 [0.37,0.87] 0.56 [0.31,0.80]
P-value 0.033 0.029
Change in SDF1a (N=9)
2 N/A 20.47 [20.77,20.17] 20.56 [21.04,20.07]
P-value 0.17 0.045
1Data are shown as Kendall’s tb with approximate 95% confidence intervals between baseline biomarkers and tumor size or outcome measures, with P-value from
Kendall’s test.
2Data are shown as Kendall’s tb with approximate 95% confidence intervals between day 28 to baseline ratios of biomarkers and outcome measures, with P-value from
Kendall’s test.
SD, stable disease; IFP, interstitial fluid pressure; IL-6, interleukin-6; PlGF, placental growth factor; sVEGFR-2, soluble vascular endothelial growth factor receptor-2;
SDF1a, stromal cell-derived factor-1-alpha.
doi:10.1371/journal.pone.0026331.t004
Figure 2. Sorafenib reduces the vessel density in sarcoma lesions. Immunostaining of CD31-positive (brown) or CD31 and a-SMA-positive
(brown and pink) tumor vessels before (A) and 28 days after (B) the initiation of sorafenib treatment. Sections were counterstained with hematoxylin.
Note the reduced vessel density and cellular content in the sorafenib-treated lesion.
doi:10.1371/journal.pone.0026331.g002
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a ‘‘pharmacodynamic biomarker’’ for agents with anti-VEGFR-2
TKI activity [24]. Indeed, a greater decrease in plasma sVEGFR-
2 correlated with better radiographic response and SD in this
study.
Interestingly, we also found significant associations between
cytokines that may mediate resistance to anti-VEGF therapy and
response: a lower baseline plasma PlGF concentration correlated
with a better radiographic response after treatment at day 28,
whereas an increase in SDF1a by day 28, correlated with a worse
radiographic response after treatment at day 28. The risk of false
positive correlations is high given the multiple comparisons and
the small sample size. However, it is notable that the same
correlations have been seen with other anti-VEGF agents in
patients with brain, rectal, and liver cancer (for plasma SDF1a),
and in patients with brain, rectal and ovarian cancer (for plasma
PlGF) [32,35,36,37,38,39].
The sorafenib-induced stabilization of tumor growth in human
carcinoma xenografts in mice is associated with a decrease in
vascular density [4,40,41]. Similarly in two sarcoma patients with
stable disease, we found that sorafenib reduced tumor vessel
density and IFP. These findings are consistent with sorafenib
inhibition of VEGF signaling. We have previously shown that
VEGF inhibition by bevacizumab significantly reduces the
vascular density and IFP in rectal carcinoma patients [19].
Because VEGF signaling inhibition also reduces the leakiness of
tumor vessels, the decrease in IFP may be caused by a reduction in
vascular permeability [20]. Sorafenib inhibition of PDGF signaling
could also lead to a reduction in IFP.
Conclusion
Sorafenib shows modest clinical activity in patients with
advanced refractory STS. Biomarker changes were consistent
with inhibition of angiogenesis by sorafenib, including a
mechanism-based decrease in the baseline high levels of intra-
tumoral IFP. Preliminary circulating biomarker data from this
study suggest a potential biomarker value for sVEGFR-2, PlGF,
and SDF1a. Tumor IFP and vessel density appear to decrease
when response is maintained. The findings of this hypothesis-
generating study should be validated in large prospective trials of
sorafenib, alone or in combination with other agents, in sarcoma
and other cancers.
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